Prevalence of mental retardation among children in Saudi Arabia.

This survey determined the prevalence and regional distribution of mental retardation among children in Saudi Arabia. Data were analysed from a population-based national survey conducted during 1996-99, in which 60,630 children aged up to 18 years were screened using IQ tests and questionnaires completed by physicians. The prevalence of mental retardation was 8.9 per 1000 children, a rate similar to that reported in other countries. Moderate or severe retardation was classified in 70.9% of these children. Of the mentally retarded children in the 0-18 years age range, 83.2% were not attending school. Special educational programmes are needed to improve the quality of life of mentally retarded children.

Prevalence of mental retardation among children in Saudi Arabia

This survey determined the prevalence and regional distribution of mental retardation among children in Saudi Arabia. Data were analysed from a population-based national survey conducted during 1996-99, in which 60,630 children aged up to 18 years were screened using IQ tests and questionnaires completed by physicians. The prevalence of mental retardation was 8.9 per 1000 children, a rate similar to that reported in other countries. Moderate or severe retardation was classified in 70.9% of these children. Of the mentally retarded children in the 0-18 years age range, 83.2% were not attending school. Special educational programmes are needed to improve the quality of life of mentally retarded children

Congenital hypothyroidism: increased incidence in Najran province, Saudi Arabia.

Neonatal screening for congenital hypothyroidism using cord serum thyroid-stimulating hormone (TSH) was initiated in Najran health region in September 1990. A total of 30810 newborn infants were screened by April 1995. Of the 24 infants with abnormal thyroid function tests on recall, 22 had permanent primary congenital hypothyroidism (incidence; 1:1400) and in two male siblings transient congenital hypothyroidism (incidence; 1:15400) was proved on follow-up. There was a significantly higher incidence of dyshormonogenesis. Eight (57 per cent) of the 14 infants who were adequately studied thyroid scan revealed ectopic glands with increased 99mTc uptake, while thyroid ectopy and aplasia were present only in three (22 per cent) infants each. Furthermore, goiter was evident clinically in two other patients.

Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience.

The regional screening program for congenital hypothyroidism (CH) in Riyadh Province was started as a pilot study in December 1988. By September 1990, the program covered all deliveries at the Ministry of Health (MOH) and King Saud University hospitals. The program utilizes cord serum thyroid-stimulating hormone (TSH) with a low recall rate of 0.1%. The average cost per specimen was SR 12 (US$ 3.20). Among 283,647 infants screened, 83 infants were confirmed to have CH (incidence 1:3417). In 17 infants, however, the diagnosis was not confirmed due to difficulties in recall. Eleven infants with cord serum TSH of more than 100 mU/L proved to be clinically and biochemically euthyroid at recall. Three of these were secondary to maternal proplthiouracil (PTU) therapy. The female to male ratio was 1.5:1. The majority of infants lacked clinical symptoms and signs of hypothyroidism. Thyroid scans showed the most common etiology to be thyroid ectopy (50%), followed by dyshormonogenesis (26%) and athyrosis (24%). Although there was no significant difference in the mean cord T4 values among the different groups, the mean T4 value at recall in the athyrotic group was significantly (P <0.001) lower than the cord results (14.8 versus 62.7) and that is of recall for the ectopic and dyshormonogenesis groups (14.8 versus 47.0 and 51.3 respectively0. There was bo significant difference in the mean TSH among the different groups in the cord and recall samples. Skeletal maturation was more delayed in the athyrotic group. The mean age at the time of recall was 16.4 days (range 4 to 64), and the mean age at the start of therapy was 17.8 days (range 5-64).